What have we learned from exceptional tumour responses?: Review and perspectives

Current Opinion in Oncology

Volumn 27, Issue 3, 2015, Pages 267-275

  Mehra, Niven ^a   Lorente, David ^a   De Bono, Johann S ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

adaptive trials; exceptional and outlier responders; molecular characterization; targeted therapy

Indexed keywords

5 (3 FLUOROPHENYL) N (3 PIPERIDINYL) 3 UREIDO 2 THIOPHENECARBOXAMIDE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ANTINEOPLASTIC AGENT; AZD 4547; AZD 8931; CHECKPOINT KINASE 1 INHIBITOR; CHECKPOINT KINASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; DNA; DOCETAXEL; DURVALUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GANETESPIB; GANITUMAB; IRINOTECAN; METFORMIN; PALBOCICLIB; PAZOPANIB; PERTUZUMAB; RILOTUMUMAB; SELUMETINIB; SORAFENIB; TASELISIB; TAXANE DERIVATIVE; TRASTUZUMAB; TREBANANIB; UNCLASSIFIED DRUG; VEMURAFENIB; TUMOR MARKER;

CANCER THERAPY; GENE MUTATION; GENOMICS; GENOTYPE PHENOTYPE CORRELATION; HUMAN; LUNG ADENOCARCINOMA; MELANOMA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TRANSITIONAL CELL CARCINOMA; DNA MUTATIONAL ANALYSIS; GENETICS; GENOTYPE; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; NEOPLASMS; PATHOLOGY; PERSONALIZED MEDICINE; PHENOTYPE; PROCEDURES;

ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; COMBINED MODALITY THERAPY; DNA MUTATIONAL ANALYSIS; GENOTYPE; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PHENOTYPE; PRECISION MEDICINE;

EID: 84928503242     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000182     Document Type: Review

References (61)

1. Freidlin B, Korn EL. Biomarker enrichment strategies: matching trial design to biomarker credentials. Nat Rev Clin Oncol 2014; 11:81-90.
2. Grasso CS, Wu Y, Robinson DR, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012; 487:239-243.
3. Collisson Ea, Campbell JD, Brooks AN, et al. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014; 511:543-550.
4. Ciriello G, Miller ML, Aksoy BA, et al. Emerging landscape of oncogenic signatures across human cancers. Nat Genet 2013; 45:1127-1133.
5. Stransky N, Egloff AM, Tward AD, et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011; 333:1157-1160.
6. Indian Project Team of the International Cancer Genome Consortium. Mutational landscape of gingivo-buccal oral squamous cell carcinoma reveals new recurrently-mutated genes and molecular subgroups. Nat Commun 2013; 4:2873.
7. Gerlinger M, Horswell S, Larkin J, et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet 2014; 46:225-233.
8. Hoadley Ka, Yau C, Wolf DM, et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 2014; 158:929-944.
9. Van Allen EM, Mouw KW, Kim P, et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov 2014; 4:1140-1153.
10. Van Allen EM, Wagle N, Sucker A, et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov 2014; 4:94-109.
11. Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014; 371:2189-2199.
12. Chang DK, Grimmond SM, Evans TRJ, Biankin AV. Mining the genomes of exceptional responders. Nat Rev Cancer 2014; 14:291-292.
13. Mullard A. Learning from exceptional drug responders. Nat Rev Drug Discov 2014; 13:401-402.
14. Abrams J, Conley B, Mooney M, et al. National Cancer Institutes precision medicine initiatives for the new National Clinical Trials Network. Am Soc Clin Oncol Educ Book 2014; 71-76.
15. Zardavas D, Maetens M, Irrthum a, et al. The AURORA initiative for metastatic breast cancer. Br J Cancer 2014; 111:1881-1887.
16. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated nonsmall-cell lung cancer. N Engl J Med 2005; 353:123-132.
17. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced nonsmall-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366:1527-1537.
18. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-2139.
19. Mok TS, Wu Y-L, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361:947-957.
20. Kwak EL, Bang Y-J, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in nonsmall-cell lung cancer. N Engl J Med 2010; 363:1693-1703.
21. Solomon BJ, Mok T, Kim D-W, et al. First-line crizotinib versus chemotherapy in ALK -positive lung cancer. N Engl J Med 2014; 371:2167-2177.
22. Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 2012; 338:221.
23. Voss MH, Hakimi AA, Pham CG, et al. Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy. Clin Cancer Res 2014; 20:1955-1964.
24. Lorenz MC, Heitman J. TOR mutations confer rapamycin resistance by preventing interaction with FKBP12-rapamycin. J Biol Chem 1995; 270:27531-27537.
25. Wagle N, Grabiner BC, Van Allen EM, et al. Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med 2014; 371:1426-1433.
26. Wagle N, Emery C, Berger MF, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 2011; 29:3085-3096.
27. Falchook GS, Trent JC, Heinrich MC, et al. BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance. Oncotarget 2013; 4:310-315.
28. Wagle N, Grabiner BC, Van Allen EM, et al. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov 2014; 4:546-553.
29. Lovly CM, McDonald NT, Chen H, et al. Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. Nat Med 2014; 20:1027-1034.
30. Al-Ahmadie H, Iyer G, Hohl M, et al. Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy. Cancer Discov 2014; 4:1014-1021.
31. Garraway LA. Genomics-driven oncology: framework for an emerging paradigm. J Clin Oncol 2013; 31:1806-1814.
32. Liu SV, Miller VA, Lobbezoo MW, Giaccone G. Genomics-based early-phase clinical trials in oncology: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies. Eur J Cancer 2014; 50:2747-2751.
33. Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 2014; 311:1998-2006.
34. André F, Bachelot T, Commo F, et al. Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncol 2014; 15:267-274.
35. Stewart DJ, Kurzrock R. Fools gold, lost treasures, and the randomized clinical trial. BMC Cancer 2013; 13:193.
36. Downing NS, Aminawung JA, Shah ND, et al. Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012. JAMA 2014; 311:368-377.
37. Berry DA. Adaptive clinical trials in oncology. Nat Rev Clin Oncol 2012; 9:199-207.
38. Kim ES, Herbst RS, Wistuba II, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 2011; 1:44-53.
39. El-Maraghi RH, Eisenhauer EA. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III. J Clin Oncol 2008; 26:1346-1354.
40. Olmos D, Arkenau H-T, Ang JE, et al. Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. Ann Oncol 2009; 20:27-33.
41. Murtaza M, Dawson S-J, Tsui DWY, et al. Noninvasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013; 497:108-112.
42. Dawson S-J, Tsui DWY, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013; 368:1199-1209.
43. Perkins G, Yap TA, Pope L, et al. Multipurpose utility of circulating plasma DNA testing in patients with advanced cancers. PLoS One 2012; 7:e47020.
44. Ong M, Carreira S, Goodall J, et al. Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail. Br J Cancer 2014; 111:828-836.
45. Kaplan R, Maughan T, Crook A, et al. Evaluating many treatments and biomarkers in oncology: a new design. J Clin Oncol 2013; 31:4562-4568.
46. Willyard C. Basket studies will hold intricate data for cancer drug approvals. Nat Med 2013; 19:655.
47. Conley BA, Doroshow JH. Molecular analysis for therapy choice: NCI MATCH. Semin Oncol 2014; 41:297-299.
48. DiMasi JA, Feldman L, Seckler A, Wilson A. Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Ther 2010; 87:272-277.
49. Yap TA, Lorente D, Omlin A, et al. Circulating tumor cells: a multifunctional biomarker. Clin Cancer Res 2014; 20:2553-2568.
50. Lorente D, Mateo J, de Bono JS. Molecular characterization and clinical utility of circulating tumor cells in the treatment of prostate cancer. Am Soc Clin Oncol Educ Book 2014; 34:e197-e203.
51. Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014; 6:224Ra24.
52. Katsuda T, Kosaka N, Ochiya T. The roles of extracellular vesicles in cancer biology: toward the development of novel cancer biomarkers. Proteomics 2014; 14:412-425.
53. Tran B, Brown AMK, Bedard PL, et al. Feasibility of real time next generation sequencing of cancer genes linked to drug response: results from a clinical trial. Int J Cancer 2013; 132:1547-1555.
54. Van Allen EM, Wagle N, Stojanov P, et al. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med 2014; 20:682-688.
55. Olmos D, Brewer D, Clark J, et al. Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. Lancet Oncol 2012; 13:1114-1124.
56. Lohr JG, Adalsteinsson VA, Cibulskis K, et al. Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol 2014; 32:479-484.
57. Pailler E, Adam J, Barthélémy A, et al. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive nonsmall-cell lung cancer. J Clin Oncol 2013; 31:2273-2281.
58. Carreira S, Romanel A, Goodall J, et al. Tumor clone dynamics in lethal prostate cancer. Sci Transl Med 2014; 6:254ra125.
59. Lebofsky R, Decraene C, Bernard V, et al. Circulating tumor DNA as a noninvasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types. MolOncol 2014. [Epub ahead of print]
60. Garraway LA, Verweij J, Ballman KV. Precision oncology: an overview. 2013, 31:1803-1805.
61. Brannon AR, Sawyers CL. N of 1 case reports in the era of whole-genome sequencing. J Clin Invest 2013; 123:4568-4570.